



Intercell AG appoints Thomas Lingelbach

Vienna (Austria), August 3, 2006 – Intercell AG (VSE, “ICLL”) today announced the recruitment of Thomas Lingelbach as Chief Operating Officer of Intercell and Managing Director of Intercell Biomedical Ltd. (Scotland), the operating site for the commercial production of Intercell's Japanese Encephalitis Vaccine. Within his function beginning on October 1st, 2006, he will play a pivotal role in establishing Intercell's commercial manufacturing as well as its further production and process development.

He started his professional career in the pharma industry in 1989 at Hoechst AG, Frankfurt (Germany). From 2001 till Chiron's acquisition by Novartis in April 2006, he served as Vice President Industrial Operations in Chiron Vaccines' Executive Committee as well as Managing Director for Chiron-Behring GmbH & Co. KG in Germany. Most recently he has been significantly involved in Novartis' Vaccines and Diagnostics integration activities acting as General Manager and Managing Director for its German Vaccines Operations.

Thomas Lingelbach successfully transformed Chiron Vaccines' industrial operations into a globally integrated function with center of excellence sites in Germany, Italy, the UK and India. He implemented key processes for technology industrialization, supply chain and industrial product management. In his capacity he played an integral part in getting Fluvirin back on the market in 2005, when he led the remediation efforts at the Liverpool site in close collaboration with MHRA and FDA. Furthermore, he enabled the Marburg site to become the first commercially viable flu cell culture manufacturing facility.

“Thomas Lingelbach's profound experience, his leadership competences and prominent position in the human vaccine field is another example of Intercell's philosophy to build a top-class worldwide business with outstanding staff”, states Gerd Zettlmeissl, Intercell's Chief Executive Officer.

About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for the prevention and treatment of infectious diseases, for which there exists a substantial unaddressed medical need. Intercell develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Sanofi Pasteur S.A., Merck & Co., Inc., SciGen Ltd., the Statens Serum Institut and Kirin Brewery Co. Ltd. Intercell has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III clinical trials, where Novartis will be the strategic partner for marketing and distribution, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccine candidates for Tuberculosis and *S. aureus*, which are in Phase I, and more than five other product candidates focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".





For picture download of Thomas Lingelbach or more information, please visit the press section on www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.